Breakthroughs in Atopic Dermatitis with Linda Stein Gold, MD: Primary Viewpoints Podcast

,

Conference | <b>AAD</b>

“I think it’s important to have a lot of tools in our toolbox, and [tapinarof cream 1%] is one that gives us great flexibility," said Linda Stein Gold, MD.

Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream 1% data from a new analysis of the ADORING-3 clinical trial. Interview recorded at the 2025 American Academy of Dermatology conference in Orlando, Florida.

Topics discussed include:

  • Key insights from the new analysis of the ADORING-3 clinical trial on the use of tapinarof cream, 1% in patients with atopic dermatitis.
  • Long-term safety and efficacy of tapinarof cream.
  • How tapinarof cream differs from existing treatment options.
  • Impacts on clinical practice.